by Clinical Neuropsychologist Online | Monday, September 21, 2026 | Dementia
Abstract INTRODUCTION Cholinergic white matter pathway (CWMP) degeneration is central in Alzheimer’s disease (AD) and Lewy body disease (LBD). CWMP degeneration can be assessed in vivo using magnetic resonance imaging (MRI) proxies, but...
by Clinical Neuropsychologist Online | Monday, September 21, 2026 | Dementia
Abstract INTRODUCTION We assessed the association between cardiovascular disease (CVD) and cognitive decline in adults aged 50 years or older using pooled data from five multinational cohorts, quantified heterogeneity, and explored its potential sources. METHODS...
by Clinical Neuropsychologist Online | Monday, September 21, 2026 | Dementia
Abstract INTRODUCTION Amyloid-beta (Aβ)-induced microvascular injury is a key pathological feature of cerebral amyloid angiopathy (CAA). Recent evidence suggests that ferroptosis is implicated in Aβ pathology; however, its cell-type specificity and regulatory...
by Clinical Neuropsychologist Online | Monday, September 21, 2026 | Dementia
Abstract INTRODUCTION Immune dysfunction has been implicated in Alzheimer’s disease (AD), but the roles of specific immunoglobulin classes remain unclear. METHODS We integrated human genetics and plasma biomarker analyses to evaluate immunoglobulin G (IgG), IgA,...
by Clinical Neuropsychologist Online | Monday, September 21, 2026 | Dementia
Abstract INTRODUCTION Type 1 diabetes mellitus (T1DM) increases dementia risk. Understanding clinical modifiers of that effect could inform prevention. METHODS We analyzed data from All of Us. Participants were aged ≥50 years with T1DM (n = 5,442) or no diabetes...
by Clinical Neuropsychologist Online | Monday, September 21, 2026 | Dementia
Alzheimer’s &Dementia, Volume 22, Issue 9, September 2026. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | September 21, 2026 Neuro-Dementia...
